Synthesis and Evaluation of Novel Carbocyclic Oxetanocin A (COA-Cl) Derivatives as Potential Tube Formation Agents

  • Sakakibara Norikazu
    Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University
  • Igarashi Junsuke
    Department of Cardiovascular Physiology, Faculty of Medicine, Kagawa University
  • Takata Maki
    Department of Pharmaco-Bio-Informatics, Faculty of Medicine, Kagawa University
  • Demizu Yosuke
    Division of Organic Chemistry, National Institute of Health Sciences
  • Misawa Takashi
    Division of Organic Chemistry, National Institute of Health Sciences
  • Kurihara Masaaki
    Division of Organic Chemistry, National Institute of Health Sciences
  • Konishi Ryoji
    Department of Pharmaco-Bio-Informatics, Faculty of Medicine, Kagawa University
  • Kato Yoshihisa
    Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University
  • Maruyama Tokumi
    Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University
  • Tsukamoto Ikuko
    Department of Pharmaco-Bio-Informatics, Faculty of Medicine, Kagawa University

この論文をさがす

抄録

Six novel carbocyclic oxetanocin A analogs (2-chloro-C.OXT-A; COA-Cl) with various hydroxymethylated or spiro-conjugated cyclobutane rings at the N9-position of the 2-chloropurine moiety were synthesized and evaluated using human umbilical vein endothelial cells. All prepared compounds (2af) showed good to moderate activity with angiogenic potency. Among these compounds, 100 µM cistrans-2′,3′-bis(hydroxymethyl)cyclobutyl derivative (2b), trans-3′-hydroxymethylcyclobutyl analog (2d), and 3′,3′-bis(hydroxymethyl)cyclobutyl derivative (2e) had greater angiogenic activity, with relative tube areas of 3.43±0.44, 3.32±0.53, and 3.59±0.83 (mean±standard deviation (S.D.)), respectively, which was comparable to COA-Cl (3.91±0.78). These data may be important for further development of this class of compounds as potential tube formation agents.

収録刊行物

被引用文献 (4)*注記

もっと見る

参考文献 (24)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ